English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA new type of anti-clotting drug caused fewer bleeding incidents among patients with atrial fibrillation than the commonly prescribed apixaban, according to results from a head-to-head comparison of the two.
Tag: Atrial fibrilation
Trial Compares Two Devices Used For Percutaneous Left Atrial Appendage Closure
SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure (LAAC) as evaluated by 45-day cardiac computed tomography angiography (CCTA). The study showed that the two devices achieve a similar rate of LAA occlusion at 45 days but through different mechanism. Furthermore, Amulet as compared with Watchman FLX was associated with higher procedural complications but similar clinical outcomes at 45-days.
Memorial Hermann First in Texas to Use Newly-Approved Device to Treat Atrial Fibrillation in Patients at Risk of Stroke
Memorial Hermann in Houston, TX is the first institution in Texas to use a new device to treat AFib in patients at risk of stroke.
Researchers Uncover Link Between Racial, Ethnic and Socioeconomic Factors and Likelihood of Getting Effective Treatment for Atrial Fibrillation
Even though the use of rhythm control strategies for treating Paroxysmal Atrial Fibrillation (AF), a common abnormal heart rhythm, have increased overall in the United States, patients from racial and ethnic minority groups and those with lower income were less likely to receive rhythm control treatment – often the preferred treatment – according to new research from the Perelman School of Medicine at the University of Pennsylvania.
Taller People Have Increased Risk for Developing Atrial Fibrillation
Taller people have an increased risk of developing atrial fibrillation, according to a new Penn Medicine study. The research is the among the first to demonstrate that height may be a causal—not correlated—risk factor for AFib.